Get the Stockscreener App
13.55
0.37%
0.05
Pre-market:
14.00
0.45
+3.32%
Lyell Immunopharma Inc stock is traded at $13.55, with a volume of 82,708.
It is up +0.37% in the last 24 hours and down -24.39% over the past month.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
See More
Previous Close:
$13.50
Open:
$13.78
24h Volume:
82,708
Relative Volume:
0.90
Market Cap:
$316.18M
Revenue:
$31,000
Net Income/Loss:
$-246.41M
P/E Ratio:
-1.0638
EPS:
-12.7377
Net Cash Flow:
$-134.42M
1W Performance:
+10.07%
1M Performance:
-24.39%
6M Performance:
-58.18%
1Y Performance:
+39.12%
1-Day Range:
$13.27
$13.96
1-Week Range:
$12.14
$14.14
52-Week Range:
$8.46
$45.00
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Name
Lyell Immunopharma Inc
Sector
Industry
Phone
650 695-0677
Address
201 HASKINS WAY, SOUTH SAN FRANCISCO
Compare LYEL vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
13.55 | 316.18M | 31,000 | -246.41M | -134.42M | -12.74 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Needham | Buy |
| Mar-09-26 | Initiated | Citizens | Mkt Outperform |
| Dec-09-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-30-24 | Downgrade | BofA Securities | Buy → Underperform |
| Jun-27-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-11-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-17-22 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | BofA Securities | Buy |
| Jul-12-21 | Initiated | Goldman | Buy |
| Jul-12-21 | Initiated | JP Morgan | Overweight |
| Jul-12-21 | Initiated | Morgan Stanley | Overweight |
View All
Lyell Immunopharma Inc Stock (LYEL) Latest News
Lyell Immunopharma CSO Gary K. Lee sells $2,459 in LYEL stock - Investing.com India
Lyell Immunopharma CSO Gary K. Lee sells $2,459 in LYEL stock By Investing.com - Investing.com South Africa
Lyell Immunopharma COO Stephen Hill sells $1,683 in shares By Investing.com - Investing.com India
Lyell Immunopharma president and CEO Lynn Seely sells $7,337 in stock - Investing.com UK
Lyell Immunopharma COO Stephen Hill sells $1,683 in shares - Investing.com UK
Lyell Immunopharma (LYEL) CEO’s 388-share tax-related stock sale detailed in Form 4 - Stock Titan
Lyell Immunopharma (LYEL) CSO reports small tax-driven sale of company shares - Stock Titan
Lyell Immunopharma (LYEL) COO’s 89-share sale tied to RSU tax withholding - Stock Titan
Lyell Immunopharma (LYEL) VP auto-sells shares to cover RSU tax withholding - Stock Titan
Lyell Immunopharma Shareholders Back Governance at 2026 Meeting - TipRanks
Lyell Immunopharma (NASDAQ: LYEL) reports 2026 shareholder meeting and director elections - Stock Titan
Citizens upgrades Lyell Immunopharma stock price target on trial progress By Investing.com - Investing.com Canada
Lyell Immunopharma: Undervalued Ahead Of A Major CAR-T Inflection (NASDAQ:LYEL) - Seeking Alpha
Lyell Immunopharma issues colorectal cancer drug safety update - MSN
Director at Lyell Immunopharma (LYEL) receives new option grant - Stock Titan
[Form 4] Lyell Immunopharma, Inc. Insider Trading Activity - Stock Titan
Lyell Immunopharma (LYEL) director awarded 9,250 stock options at $13.22 - Stock Titan
Lyell Immunopharma (LYEL) director granted 9,250 stock options at $13.22 - Stock Titan
Lyell Immunopharma (LYEL) director receives 9,250-share option grant - Stock Titan
Lyell Immunopharma (LYEL) director receives 9,250 options at $13.22 strike - Stock Titan
Lyell Immunopharma (LYEL) director receives option grant for 9,250 shares at $13.22 - Stock Titan
Lyell reports safety data for ronde-cel in lymphoma trial By Investing.com - Investing.com Canada
Lyell Immunopharma Shows Updated Safety Data For Ronde-Cel In Patients With Large B-Cell Lymphoma - TradingView
New Safety Data and Translational Findings for Ronde-cel in Relapsed or Refractory Large B-Cell Lymphoma Announced by Lyell Immunopharma - Quiver Quantitative
Over 100 lymphoma patients get CAR-T with no Grade 3+ CRS - Stock Titan
Lyell Immunopharma (LYEL) CMO logs small tax-driven stock sale on Form 4 - Stock Titan
LYEL Reiterated by HC Wainwright & Co. -- Price Target Maintained at $45 - GuruFocus
H.C. Wainwright reiterates Lyell Immunopharma stock rating on safety data By Investing.com - Investing.com Canada
Is Lyell Immunopharma (NASDAQ:LYEL) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Citizens upgrades Lyell Immunopharma stock rating on safety data By Investing.com - Investing.com Canada
Lyell Immunopharma amends LYL273 Phase 1 trial to Phase 1/2 - grafa.com
Lyell Immunopharma Issues Colorectal Cancer Drug Safety Update - Benzinga
Lyell Immunopharma stock rises on trial amendment - Investing.com UK
Lyell Immunopharma stock rises on trial amendment By Investing.com - Investing.com Canada
Lyell Immunopharma's Cancer Therapy Shows Improved Safety in Phase 1 Study - Moomoo
Lyell Immunopharma Reports Significant Reduction in Grade ≥ 2 Diarrhea/Colitis in Phase 1 Trial of LYL273 for Metastatic Colorectal Cancer with GI Prophylaxis - Quiver Quantitative
Lyell Immunopharma Provides Update on Safety Profile of - GlobeNewswire
New regimen cuts gut side effects in Lyell's LYL273 colon cancer trial - Stock Titan
Lyell Immunopharma, Inc.Common Stock (NQ: LYEL - FinancialContent
Lyell to present ronde-cel lymphoma trial data at EHA congress - Investing.com Australia
Lyell Immunopharma to Present Phase 1/2 Ronde-Cel Safety and Translational Data in Large B-Cell Lymphoma at EHA 2026Profit Recovery Report - newsline.com
Lyell to present ronde-cel lymphoma trial data at EHA congress By Investing.com - Investing.com South Africa
Lyell Immunopharma to Present Phase 1/2 Clinical Trial Data on Rondecabtagene Autoleucel at EHA 2026 Congress - Quiver Quantitative
Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress - GlobeNewswire
Lyell Immunopharma (LYEL) Loses 39.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Lyell Immunopharma, Inc. Stock 12‑Month Price Target Cut to $37.17, Implies 150% Upside - TradingView
H.C. Wainwright reiterates Lyell Immunopharma stock rating at buy By Investing.com - Investing.com Canada
Lyell Immunopharma Q1 2026 Earnings: EPS Beats Estimates by 54.4% as Stock Declines 13.18% - newsline.com
Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026 - The Manila Times
Lyell Quiet as Bigger CAR-T Question Lingers for Investors - Bez Kabli
Lyell Immunopharma (LYEL) Holds Steady With Modest Gains Amid Technical ConsolidationFactor ETF Flow - newsline.com
Lyell Immunopharma Inc Stock (LYEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):